The FDA issued an emergency use authorization (EUA) yesterday for the investigational monoclonal antibody therapy bamlanivimab (LY-CoV555) to treat COVID-19. The drug from Eli Lilly (NYSE:LLY) is intended to reduce the risk of severe COVID-19 infections when administered within 10 days of developing symptoms. The manufacturer indicates the drug for mild-to-moderate COVID-19 infections in adult…